REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Targeting the P2X7 Receptor in Cerebrovascular Diseases: From Molecular Mechanisms to Preclinical Therapeutic Potential
Provisionally accepted
- 1Department of Anesthesiology, Nanchang University Second Affiliated Hospital, Nanchang, China
- 2The Second Clinical Medical College of Nanchang University, Nanchang University, Nanchang, China
- 3Nanchang University Queen Mary School, Nanchang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cerebrovascular diseases seriously damage human health and impose a huge burden on society. Research on the mechanisms of cerebrovascular disease occurrence and development is of great significance in preventing the occurrence of the disease and improving the quality of life of patients. P2X7 Receptor (P2X7R), as a non-selective cation channel of the purinergic receptor family, is considered to be expressed in various immune cells within the nervous system and may also be expressed in neurons. Recent studies have identified P2X7R as a significant player in the progression of cerebrovascular diseases, potentially linked to its role in regulating neuroinflammation, cellular autophagy, and vascular function. This review elucidates the biological foundation of P2X7R, compiles various molecular mechanisms associated with cerebrovascular diseases, emphasizes recent research on the involvement of P2X7R in the pathogenesis of cerebrovascular diseases, and assesses the pharmacological implications of P2X7R in these conditions. By exploring the connections between P2X7R and cerebrovascular diseases, the therapeutic potential of targeting P2X7R in these conditions can be assessed, ultimately paving the way for novel therapeutic strategies to ameliorate the impact of cerebrovascular diseases.
Keywords: P2X7R, cerebrovascular diseases, Pathogenesis, antagonists, Pharmacology
Received: 26 Sep 2025; Accepted: 17 Nov 2025.
Copyright: © 2025 Ziyan, Shu Jing, Chen, Luo, Deng and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiao Deng, dengxiao110409@126.com
Renjie Xiao, shentanx@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.